急性髓系白血病t(8;21)中BRCC3突变的功能特征
研究探讨了BRCC3突变在t(8;21)(q22;q22.1)急性髓系白血病(AML)中的功能。在191例t(8;21) AML中检出9例(4.7%)BRCC3突变,患者无事件生存率达100%。BRCC3失活促进细胞增殖、增强自我更新、削弱干扰素和炎症小体反应,并增加对多柔比星的敏感性。
要点
- BRCC3突变在t(8;21) AML中占4.7%(9/191),inv(16) AML中未检出。
- BRCC3突变患者无事件生存率为100%,提示预后良好。
- BRCC3失活导致DNA损伤应答受损,增加多柔比星敏感性。
核心结论
- BRCC3突变在t(8;21) AML中选择性出现,与极佳预后相关。
- BRCC3失活通过增强增殖、自我更新及干扰素/炎症小体信号受损促进白血病发生。
研究设计与样本
- 研究纳入191例t(8;21)(q22;q22.1) AML和160例inv(16)(p13.1q22) AML进行BRCC3突变分析。
- 采用CRISPR/Cas9敲除BRCC3,在t(8;21)阳性AML细胞系和小鼠造血祖细胞中进行功能实验。
主要发现
- 9/191(4.7%)例t(8;21) AML携带BRCC3突变,160例inv(16) AML中无BRCC3突变。
- BRCC3突变AML患者无事件生存率为100%。
- CRISPR/Cas9失活BRCC3促进t(8;21)阳性AML细胞系增殖,与AML1-ETO共表达诱导小鼠造血祖细胞体外无限自我更新。
- BRCC3突变消除其对IFNAR1的去泛素化活性,损害干扰素反应并降低炎症小体活性。
- BRCC3失活增加包括G-CSF在内的多种细胞因子释放,增强t(8;21)阳性AML细胞系增殖。
临床怎么用
- t(8;21) AML患者可考虑检测BRCC3突变以辅助预后分层。
- BRCC3突变提示对多柔比星可能更敏感,或可指导化疗选择。
局限性
- 研究样本量有限,BRCC3突变患者仅9例,需更大队列验证。
- 功能实验主要基于细胞系和小鼠模型,临床转化需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BRCA1/BRCA2-containing complex 3 (BRCC3) is a Lysine 63-specific deubiquitinating enzyme (DUB) involved in inflammasome activity, interferon signaling, and DNA damage repair. Recurrent mutations in BRCC3 have been reported in myelodysplastic syndromes (MDS) but not in de novo AML. In one of our recent studies, we found BRCC3 mutations selectively in 9/191 (4.7%) cases with t(8;21)(q22;q22.1) AML but not in 160 cases of inv(16)(p13.1q22) AML. Clinically, AML patients with BRCC3 mutations had an excellent outcome with an event-free survival of 100%. Inactivation of BRCC3 by CRISPR/Cas9 resulted in improved proliferation in t(8;21)(q22;q22.1) positive AML cell lines and together with expression of AML1-ETO induced unlimited self-renewal in mouse hematopoietic progenitor cells in vitro. Mutations in BRCC3 abrogated its deubiquitinating activity on IFNAR1 resulting in an impaired interferon response and led to diminished inflammasome activity. In addition, BRCC3 inactivation increased release of several cytokines including G-CSF which enhanced proliferation of AML cell lines with t(8;21)(q22;q22.1). Cell lines and primary mouse cells with inactivation of BRCC3 had a higher sensitivity to doxorubicin due to an impaired DNA damage response providing a possible explanation for the favorable outcome of BRCC3 mutated AML patients.
引用
- Meyer T, Jahn N, Lindner S, et al. Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). Leukemia. 2019. PMID: 31576005. doi:10.1038/s41375-019-0578-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。